Epkinly (epcoritamab-bysp) / Genmab, AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epkinly (epcoritamab-bysp) / Genmab, AbbVie
NCT06447376: Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Recruiting
1
20
US
Siltuximab, Epcoritamab
Taylor Brooks, Genmab, AbbVie, Recordati Rare Diseases
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
09/28
09/28
NCT06672705: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Recruiting
1
26
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Epcoritamab, Anti-CD20/CD3 Bispecific Antibody GEN3013, DuoBody-CD3xCD20, Epcoritamab-bysp, Epkinly, GEN 3013, GEN-3013, GEN3013, Tepkinly, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
Timothy Voorhees, AbbVie, Genmab
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
12/26
12/26
NCT06676033: Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Recruiting
1
30
US
epcoritamab
National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Chronic Lymphocytic, Richter Syndrome
07/27
07/27
EIFEL, NCT07082868: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Recruiting
1
26
US
ibrutinib, Epcoritamab
Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
08/28
08/28
EPCORE Peds-1, NCT05206357 / 2021-004555-16: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Active, not recruiting
1
17
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013
Genmab, AbbVie
Non-hodgkin Lymphoma
11/28
11/28

Download Options